newsfilter
← Latest News
GlobeNewswire·

Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update

On track for top-line trial results in the third quarter of 2026 from pivotal Phase 2b clinical trial ELPIS II. ELPIS II is evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and